IVF is a type of assisted reproduction technology in which a woman's reproductive system is artificially encouraged to create oocytes, which are then harvested, fertilized in a lab, and placed in the uterus. Due to complications, IVF specialist provide drugs and food supplements to patients undergoing IVF treatment. IVF treatment procedure includes ovarian stimulation, ovulation induction, oocyte harvest, sperm fertilization, and transport of the fertilized oocytes for implantation. There are various drugs which are commonly used for IVF treatment such as Clomiphene used for inducing ovulation and also injectables available for IVF treatment which includes gonadotropin-releasing hormone (GnRH) and follicle-stimulating hormone (FSH), that produce progesterone to maintain the pregnancy. GonGnRH antagonist inhibit of a premature LH rise and also there are various food supplements which are commonly provided to the patients under IVF treatment such as Coenzyme Q10 (CoQ10) to improve egg quality, sperm quality, and pregnancy rates and DHEA used as an adjuvant for in vitro fertilization (IVF) cycles in poor ovarian responders.
The UAE IVF drugs and food supplements market is estimated to be valued at US$ 20.4 million in 2022, and is expected to exhibit a CAGR of 6.6% during the forecast period (2022-2030).
Figure 1. UAE IVF Drugs and Food Supplements Market Share in Terms of Value (US$ Mn), By Product Type, 2021
Favourable initiatives by regulatory authorities for IVF in the country are likely to propel the market growth over the forecast period.
Government initiative for IVF treatment development is expected to drive the UAE IVF drugs and food supplements market over the forecast period in the country. For instance, on October 19, 2019, the President of the United Arab Emirates (UAE), announced the new IVF law. The new IVF law officially came into force from January 1, 2020, repealing the old IVF law. The executive regulations which sit alongside the new IVF law were published in the Official Federal Gazette which includes the laws such as fertility centers are now permitted to freeze human embryos for a period of five years (extendable upon request). Under the new IVF law, subject to compliance with certain controls and procedures, samples of frozen unfertilized or fertilized eggs or sperm may be taken abroad, if prepared in the UAE, or brought into the UAE, if prepared abroad. The new IVF law makes provision for the establishment of a national advisory committee that submits recommendations and proposals in relation to medically assisted reproduction and coordinates between the relevant regulatory authorities in the UAE.
|Base Year:||2021||Market Size in 2022:||
US$ 20.4 Mn
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||6.6%||2030 Value Projection:||
US$ 33.9 Mn
Shinelife, Adorefem, LG Chem, Adorshea, Biofield Pharma, Medibyte, Mestra Pharma, Dr. D Pharma, Abbott, Zydus, Takeda Pharmaceutical Company Limited, Merck KGaA, and Ferring B.V.
|Restraints & Challenges:||
Figure 2. UAE IVF Drugs and Food Supplements Market Share (%), By Distribution Channel, 2021
Market players are indulged in inorganic activities such as partnership, acquisition, and collaboration, which is expected to drive the market growth during the forecast period.
Market players are indulged in inorganic activities such as partnership, acquisition and collaboration, which is expected to propel growth of the UAE IVF drugs and food supplements market during the forecast period. For instance, on March 29, 2019, Boston IVF, an infertility treatment service provider and Ohio Reproductive Medicine, an infertility center, announced new partnership. Moreover, the aim of this partnership is to advance the Ohio Reproductive Medicine’s mission to deliver world-class fertility treatments and care, including in vitro fertilization (IVF), genetic testing, male factor, LGBTQ+ family building, egg freezing, and others. With technology and research playing an increasingly critical role in the quality of patient care, future initiatives will include opportunities for ORM to benefit from Boston IVF’s innovative science that improves IVF outcomes and lessens time in treatment at global level which is expected to cover the UAE IVF drugs and food supplements market owing to the research and development for fertility issues in upcoming years.
UAE IVF Drugs and Food Supplements Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic is expected to hamper growth of the UAE IVF drugs and food supplements market during the forecast period. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 340 million cases and 5,570,163 deaths due to coronavirus disease (COVID-19) were reported up till January 23, 2022, across the global.
Furthermore, many hospitals maximize wellbeing of patients, staff, and society at large. There is a confusing picture of the effect of COVID-19 on fertility treatments, with the advice and guidance coming from several different resources such as ASRM (American Society of Reproductive Medicine) stated that in year 2020 some women have postponed their IVF consultations, whereas others have delayed their dates of embryo transfer until the pandemic situation ends and life comes back to normal. According to The U.S.-U.A.E. Business Council In the midst of this public health crisis, the healthcare landscape in the U.A.E. has changed in significant ways, as new key entities launching and consolidating. Abu Dhabi Developmental Holding Company (ADQ), an investment management company that had a broad portfolio of important healthcare enterprises in Abu Dhabi such as Abu Dhabi Health Services Company (SEHA), continued its expansion into the healthcare space by launching Union 71, a laboratory testing company, and Rafed, a Group Purchasing Organization to manage and develop the procurement of healthcare-related services and products after the emergence of these two groups, ADQ signed an agreement merging both Rafed and Union71 with Pure Health, a key integrated healthcare solutions provider in the U.A.E.
UAE IVF Drugs and Food Supplements Market: Restraint
The higher cost of treatment as compared to other countries in the UAE is considered the major limiting factor for more patients coming from abroad. However, based on Colliers’s discussions with major providers in the UAE which states that the high success rates and quality are directly related to the significant investments made in this sector both in equipment and staff. If treatment fees for IVF are substantially reduced, it will have an impact on the UAE’s ability to retain the IVF facilities.
Major players operating in the UAE IVF drugs and food supplements market include Shinelife, Adorefem, LG Chem, Adorshea, Biofield Pharma, Medibyte, Mestra Pharma, Dr. D Pharma, Abbott, Zydus, Takeda Pharmaceutical Company Limited, Merck KGaA, and Ferring B.V.
In vitro fertilization (IVF) is a form of assisted reproductive technology in which a woman’s reproductive system is artificially stimulated to produce oocytes, which are extracted, fertilized in a laboratory, and then implanted in the uterus. This is a multistep process that needs to be carefully controlled with the use of medications due to the complex interplay of the various drugs used to replicate the different stages of the fertilization process by IVF healthcare team. IVF is a multistep process involving ovarian stimulation, ovulation induction, collection of oocytes, fertilization with sperm, and transfer of the fertilized oocytes to the uterus for implantation and maturation by following various stages. At each stage, there are different protocols for the use of these drugs, and the most appropriate pharmacologic regimen and therapeutic intervention are chosen after a thorough pre-treatment evaluation and an accurate diagnosis, controlled ovarian stimulation is achieved with the use of gonadotropin-releasing hormone (GnRH) analogues and inhibitors of natural steroid hormones, such as clomiphene citrate, recombinant follicle-stimulating hormone (FSH), and luteinizing hormone (LH) and also by providing food supplements to patients, such as Coenzyme Q10 (CoQ10) and DHEA are two supplements that are often used to help older women (over 35) and those with limited ovarian reserve. These are commonly used by women who are undergoing IVF to boost the number of eggs generated by their ovaries.
Key players and market players operating in the market are focusing on expanding and developing efficient IVF facilities which can be attributed to the growth of the UAE IVF drugs and food supplements market. For instance, on November 14, 2021, Mediclinic Middle East, which is a part of Mediclinic International and hospital group that operates seven hospitals in the UAE announced the 100% acquisition of Bourn Hall Fertility Centre, an IVF specialties center in the MENA region from TVM Capital Healthcare, following an initial acquisition of 30% of the shares in December 2018.The aim of this acquisition is to provide the highest level of quality care with exceptional outcomes through this acquisition to provide better services for IVF facilities.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.